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Michael W. Cullen, MD,* Allison K. Cabalka, MD,y Oluseun O. Alli, MBBS,z
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Joseph F. Malouf, MD,* Frank Cetta, MD,*y Donald J. Hagler, MD,*y
Charanjit S. Rihal, MD, MBA*
Rochester, Minnesota; and Birmingham, AlabamaObjectives The purpose of this study was to report the results of percutaneous valve-in-valve therapy
using the Melody valve (Medtronic, Minneapolis, Minnesota) for patients with degenerated mitral and
tricuspid bioprosthetic valves.
Background Open surgery for replacement of degenerated bioprosthetic valves is associated with
morbidity and mortality.
Methods Nineteen patients (median age 65 years, range 10 to 88 years; 7 males) with degenerated
mitral (n ¼ 9) or tricuspid (n ¼ 10) bioprosthetic valves underwent transvenous valve-in-valve
implantation of the Melody valve.
Results In the mitral patients, the mean Society of Thoracic Surgeons mortality score was 13.3 
5.6%. All patients had a prosthetic valve mean diastolic inﬂow gradient 5 mm Hg. Moderate or worse
regurgitation was present in 7 of 9 mitral and 7 of 10 tricuspid patients. Implantation of a Melody
valve was successful in all. Among the mitral patients, mean diastolic gradient decreased from 12.3 
4.6 mm Hg to 5.2  2 mm Hg (p < 0.01). Residual regurgitation was trivial to mild in 6, mild to
moderate in 2, and moderate in 1 patient. Among the tricuspid patients, mean diastolic gradient
decreased from 10.0  4.3 mm Hg to 5.6  2.5 mm Hg (p < 0.01). Residual regurgitation was trivial to
mild in 9 and mild to moderate in 1 patient. New York Heart Association functional class improved in
17 of 19 patients (p < 0.01). No periprocedural deaths, myocardial infarctions, strokes, or valve
embolizations occurred. Vascular access site complications occurred in 4 patients.
Conclusions Percutaneous valve-in-valve implantation of the Melody valve in the mitral or tricuspid
position for treatment of bioprosthetic valve dysfunction is feasible and can lead to signiﬁcant
symptomatic improvement in carefully selected high-risk patients. (J Am Coll Cardiol Intv
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599Bioprosthetic valves are frequently used for patients with
acquired and congenital cardiac disease despite the valves’
tendency toward earlier degeneration and valvular dysfunc-
tion (1). For patients who require treatment of degenerated
bioprosthetic valves, repeat sternotomy and open surgery
carry higher risk, especially in older patients with comorbid
conditions (2,3). Transcatheter implantation of percutane-
ously delivered valves into degenerated bioprostheses (i.e.,
valve-in-valve therapy) has emerged as an alternative to open
surgery. Reports have described valve-in-valve therapy in all
4 native valve positions (4–17), but the greatest application
has been for aortic bioprosthetic degeneration.
The Melody valve (Medtronic, Minneapolis, Minnesota)
is a bovine jugular venous valve designed and approved for
percutaneous implantation in the pulmonary position in
patients with dysfunctional right ventricular to pulmonary
artery conduits and pulmonary bioprosthetic valves or
homografts (18,19). Valve-in-valve Melody implantation
has been reported for treatment of degenerated tricuspid
bioprosthesis (5,20,21), but not for the treatment of left-
sided degenerated bioprosthetic valves.
This series describes the clinical feasibility and efﬁcacy of
percutaneous implantation of the Melody valve in patients
with degenerated bioprosthetic mitral or tricuspid valves.
Methods
Patient population. The study was approved by the Mayo
Clinic Institutional Review Board. From July 2011 through
November 2012, 19 patients underwent percutaneous
implantation of the Melody valve into the mitral (n ¼ 9) or
tricuspid (n ¼ 10) position. Patients were considered
candidates for the procedure if they had signiﬁcant bio-
prosthetic mitral or tricuspid valve dysfunction (either
stenosis, regurgitation, or both) with comorbid conditions
that would preclude a repeat sternotomy and valve replace-
ment. Consultation with a cardiac surgeon occurred before
proceeding with percutaneous valve-in-valve therapy. All
patients or parents received detailed instruction on the
potential risks of the procedure, including the off-label use of
the Melody valve. Alternatives, including repeat open surgery
and medical therapy, were carefully discussed. All patients or
parents provided informed consent for the procedure.
Mitral valve-in-valve procedure. The mitral valve-in-valve
procedure was performed in the cardiac catheterization
laboratory (Fig. 1). Patients were placed under general
endotracheal anesthesia. Intraprocedural imaging was per-
formed with transesophageal echocardiography (TEE).
Transseptal puncture was performed using standard tech-
niques. The atrial septum was sequentially dilated with 14-F
and 21-F dilators. A 20-F Dry Seal sheath (Gore Medical,
Flagstaff, Arizona) was introduced into the right femoral
vein, and an 8.5-F medium curve Agilis sheath (St. Jude
Medical, St. Paul, Minnesota) was placed in the left atriumover a Torayguide guidewire (Toray Industries, Tokyo,
Japan). Unfractionated heparin (100 U/kg) was administered
to ensure adequate systemic anticoagulation, and the acti-
vated clotting time was monitored regularly to maintain
a level >250 s.
Coronary angiography was performed to delineate the
course of the left anterior descending coronary artery and its
major branches before left ventricular puncture. The left
ventricular apical puncture was performed with an 18-gauge
needle or a One-Step Centesis Catheter (Merit Medical
Systems, South Jordan, Utah) under ﬂuoroscopic and trans-
thoracic echocardiography guidance. A 6-F sheath was then
advanced into the left ventricle over a 0.038-inch wire (22).
An exchange length 0.035-inch angled extra-support
glide wire (Terumo, Somerset, New Jersey) was introduced
through the Agilis sheath into the left atrium and advanced
across the mitral bioprosthesis into the left ventricle. The
glide wire was snared in the left ventricle and exteriorized
through the left ventricular apical sheath, creating a wire rail
between the right femoral vein and the left ventricular apex
(Fig. 1C). In selected cases, a 5-F pacing catheter was
advanced into the right ventricle
via the left femoral vein. The
internal diameter of the dys-
functional valve was measured
with TEE, and balloon sizing
performed with a compliant
balloon in selected cases. Balloon
sizing was not performed if it
was apparent the internal diam-
eter of the existing bioprosthetic
valve would support the Melody
valve. In all cases, the Melody
valve was mounted onto the 22-mm Ensemble delivery
system (Medtronic) and delivered antegrade via the right
femoral vein, across the atrial septum, and into the
dysfunctional prosthesis over the arteriovenous rail. The
valve was carefully positioned across the bioprosthesis and
deployed under rapid ventricular pacing using ﬂuoroscopy
and TEE guidance. The left ventricular apical puncture site
was subsequently closed with a 6-mm Amplatzer Vascular
Plug II (AVP II, St. Jude Medical) that expanded to ﬁll the
left ventricular apical defect. Anticoagulation was reversed
with protamine, and the venous sheath site was closed with
a ﬁgure-of-eight suture (23).
Tricuspid valve-in-valve procedure. The tricuspid valve-
in-valve procedure was performed in the cardiac catheteri-
zation laboratory under general anesthesia for 9 patients and
conscious sedation for 1 patient (Fig. 2). Imaging was per-
formed with intracardiac echocardiography (ICE) in 7
patients and TEE in 3 patients. The valve was delivered
either through the right internal jugular vein or the right
femoral vein. An extra-stiff 0.035-inch exchange length
Amplatz wire was advanced into a distal pulmonary artery
Figure 1. Mitral Valve Implantation
(A) A severely stenotic mitral valve bioprosthesis on 3-dimenstional transesophageal echocardiography (TEE). (B) Snare of the transseptal catheter via the left
ventricular apex. (C) A photo of the femoral vein to left ventricular rail externalized through the left thoracic cavity (previously published and reproduced with
permission) (16). (D) Balloon valvuloplasty of the dysfunctional bioprosthetic valve on 3-dimensional TEE. (E) A post-implant view of the deployed Melody valve from
a ventricular view on 3-dimensional TEE. (F) The deployed Melody valve inside the surgically placed bioprosthetic valve. The occluder plug used to close the left
ventricular puncture is also visible.
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600through a balloon wedge catheter. Balloon sizing of the
prosthesis was then performed with a 22-mm Z-Med II
balloon (NuMed, Hopkinton, New York). The Melody
valve was mounted onto the 22-mm Ensemble delivery
system, advanced over the exchange wire, and maneuvered
across the dysfunctional tricuspid prosthesis. Position was
conﬁrmed, and the valve was deployed under ﬂuoroscopic
and echocardiographic imaging. The venous access site was
subsequently closed with a ﬁgure-of-eight suture (23).
Data analysis. Society of Thoracic Surgeons (STS) risk
score was calculated for the mitral valve patients using the
mitral valve replacement algorithm. Clinical events for
myocardial infarction, stroke, emergency surgery, bleeding,
and vascular complications were deﬁned using standard
criteria (24–26). Continuous variables were expressed as
mean  SD if normally distributed or median with inter-
quartile range if skewed. Normal distribution was tested
with the Shapiro-Wilk statistic, and logarithmic trans-
formations were performed when appropriate. Paired t tests
and Wilcoxon signed rank tests compared pre- and post-
procedure variables within patients. We deﬁned surveillance
period as the time between the procedure and the last
clinical contact with the patient. Analyses were performed
using JMP statistical software, version 9 (SAS Institute,
Cary, North Carolina).Results
Patient population. Table 1 outlines the baseline clinical
characteristics of the study patients. Seven of 19 (37%) were
male. The mean age was 75  11 years for the mitral
patients and 42  24 years for the tricuspid patients. Three
of the 10 tricuspid valve implant patients were 18 years of
age. Median age of the dysfunctional valve was 6 (4 to 11)
years. The size of the dysfunctional valve outer sewing ring
ranged from 27 to 29 mm for the mitral valve patients and
from 25 to 33 mm for the tricuspid valve patients. Measured
internal diameter of the dysfunctional valve was 18 to 22
mm in the mitral patients by TEE and 17 to 23 mm in the
tricuspid patients by balloon sizing. According to the
manufacturers’ speciﬁcations, the reported internal diameter
of the dysfunctional valves was 24 to 28 mm in the mitral
patients and 20.5 to 31 mm in the tricuspid patients. Mean
STS risk score for mortality risk in the mitral valve patients
was 13.3  5.6%. Despite high surgical risk, 2 of the 9
mitral patients and 4 of the 10 tricuspid patients were
potentially candidates for either percutaneous valve-in-valve
implantation or open surgical repair. After a multidisci-
plinary “heart team” discussion, the patients elected the
percutaneous procedure. The other 7 mitral and 6 tricuspid
cases were too high risk for conventional valve surgery and
Figure 2. Tricuspid Valve Implantation
(A) A 3-dimensional transesophageal echocardiography (TEE) image of a severely degenerated tricuspid bioprosthetic valve with destruction of the septal leaﬂet
and poor leaﬂet coaptation. (B) Severe tricuspid regurgitation on pre-procedure 2-dimensional TEE. (C) A ﬂuoroscopic image of Melody valve deployment inside
a dysfunctional bioprosthetic valve. (D) A 3-dimensional TEE image from a ventricular view of the Melody valve aligning with the prosthetic valve struts.
(E) Trivial post-procedure tricuspid regurgitation on 2-dimensional TEE. (F) The deployed Melody valve on 3-dimensional TEE.
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601underwent percutaneous valve-in-valve replacement as an
alternative to medical therapy alone. Four of the 10 tricuspid
valve patients had congenital heart disease, including 3 with
Ebstein’s anomaly and 1 with pulmonary valve stenosis and
tricuspid valve dysplasia. Three of the 10 tricuspid patients
had signiﬁcant ascites.
At baseline, mean diastolic inﬂow gradient was 12.3 
4.6 mm Hg among the mitral patients. Seven of the 9 mitral
patients had moderate or worse bioprosthetic mitral valve
regurgitation. Mean baseline diastolic inﬂow gradient was
10  4.3 mm Hg among the tricuspid patients. Seven of the
10 tricuspid patients had moderate or worse tricuspid valve
regurgitation (Table 2).
Procedures. All patients underwent successful implantation
of a 22-mm Melody valve into the existing dysfunctional
bioprosthetic valve. Table 3 displays the procedure charac-
teristics according to valve-in-valve implantation position.
No periprocedural death, myocardial infarction, stroke,
stent fracture, or valve embolization occurred in either the
mitral or tricuspid patients. Vascular complications occurred
in 4 patients. These included a right iliac artery dissection
treated endovascularly, a right thigh hematoma treated
endovascularly, a left femoral artery pseudoaneurysm treated
surgically, and bleeding at the femoral access site that
responded to conservative therapy. Two patients developed
a left hemothorax requiring chest tube draining, likelyrelated to the left ventricular apical puncture. One mitral
valve patient required closure of the transseptal puncture site
with an Amplatzer septal occluder (St. Jude Medical) due to
signiﬁcant bidirectional shunting across the transseptal
puncture site.
Hemodynamic outcomes. Mean diastolic inﬂow gradient
decreased from 12.3 4.6 mmHg to 5.2 2 mmHg for the
mitral valve patients (Fig. 3B) (p < 0.01) and from 10  4.3
mm Hg to 5.6  2.5 mm Hg for the tricuspid valve implants
(Fig. 3B) (p < 0.01). Degree of valve regurgitation improved
after valve-in-valve implantation. In the mitral valve patients,
post-procedure regurgitation was undetectable in 2 patients,
trivial in 2 patients, mild in 2 patients, mild to moderate in 2
patients, and moderate in 1 patient (Table 2). In the tricuspid
valve patients, post-procedure regurgitation was trivial in 5
patients, mild in 4 patients, and mild to moderate in 1 patient
(Table 2).
Early outcomes. No patients died during hospitalization.
Median duration of hospitalization was 5 (1 to 14) days for
all patients, 9 (5 to 15) days for the mitral valve patients, and
2 (1 to 9) days for the tricuspid valve patients.
Median follow-up was 41 (11 to 209) days for all patients.
Three tricuspid valve patients were readmitted within
30 days of their procedure: 1 patient had a femoral artery
pseudoaneurysm requiring surgical repair and 1 patient had
fever due to phlebitis. An 11-year-old congenital patient
Table 1. Baseline Clinical and Echocardiographic Characteristics
Patient
#*
Age
(Years) Sex
Dysfunctional
Valve Position
Valve
Size (mm)
Valve
Type
Valve
age (yrs)
LV
EF (%)y
STS Mortality
Score (%)
Number of
Previous
Sternotomies
Previous
Coronary
Revascularization
1 85 M Mitral 27 d 8 62 23.8 2 Yes
2 70 F Mitral d d 9 41 8.1 1 Yes
3 88 M Mitral d d 10 63 19.0 1 No
4 84 M Mitral 27 Carpentier-Edwards 6 30 10.9 1 Yes
5 83 M Mitral 29 Carpentier-Edwards 11 30 14.1 2 No
6 75 F Mitral 29 Carpentier-Edwards 17 69 6.0 1 No
7 65 F Mitral 27 St. Jude porcine 2 65 10.9 3 No
8 57 F Mitral 27 Baxter-Edwards 14 25 11.0 1 No
9 66 F Mitral 27 Medtronic Mosaic 4 65 16.2 1 Yes
10 17 F Tricuspid 25 Medtronic Mosaic 7 30 d 4 No
11 12 F Tricuspid 25 St. Jude Biocor 5 63 d 2 No
12 58 F Tricuspid 33 Carpentier-Edwards 11 65 d 1 No
13 72 F Tricuspid 33 Carpentier-Edwards 6 35 d 2 No
14 76 M Tricuspid 27 Medtronic Mosaic 5 60 d 3 Yes
15 10 M Tricuspid 25 St. Jude porcine 2 65 d 1 No
16 50 F Tricuspid 29 Baxter-Edwards 6 57 d 1 No
17 30 F Tricuspid 31 St. Jude porcine 2 55 d 2 No
18 59 F Tricuspid 20 Medtronic Mosaic 5 67 d 1 No
19 38 M Tricuspid d Hancock porcine 26 33 d 3 No
*Patients are listed in chronological order of procedure, according to dysfunctional valve position. yData from pre-procedure transthoracic echocardiogram.
LV EF ¼ left ventricular ejection fraction; STS ¼ Society of Thoracic Surgeons.
Table 2. Pre-Implant and Post-Implant Functional Status and Hemodynamic Characteristics
Patient
#
Dysfunctional
Valve Position
NYHA Functional
Classiﬁcation
Diastolic
Gradient (mm Hg)
Prosthetic
Regurgitation
Right Atrial
Pressure (mm Hg)
Pre-Implant Post-Implant Pre-Implant* Post-Implanty Pre-Implant* Post-Implanty Pre-Implant* Post-Implanty
1 Mitral 4 3 15 5 Moderate Trivial d d
2 Mitral 3 2 12 4 Moderate–severe Mild–moderate d d
3 Mitral 4 3 9 9 Moderate–severe Mild d d
4 Mitral 3 2 14 3 Moderate–severe None d d
5 Mitral 3 4x 17 5 Mild–moderate None d d
6 Mitral 3 1 9 4 Severe Trivial d d
7 Mitral 3 2 10z 8 Severez Moderatez d d
8 Mitral 4 2 20 5 None Mild d d
9 Mitral 4 2 5 4 Severe Mild–moderate d d
10 Tricuspid 2 1 9 3 Severe Trivial 13 11
11 Tricuspid 2 1 12 8 Severe Mild 16 12
12 Tricuspid 4 2 20 7 Trivial Trivial 23 21
13 Tricuspid 3 1 7 4 Severe Mild–moderate 21 18
14 Tricuspid 3 1 9 9 Mild Trivial 20 20
15 Tricuspid 2 4k 7 6 Severe Trivial 14 9
16 Tricuspid 4 2 12 4z Mild–moderatez Trivialz 29 29
17 Tricuspid 3 1 7 2z Severe Mildz 18 16
18 Tricuspid 4 3 5 4 Severe Mild 21 30
19 Tricuspid 1 1 12 9 Severe Mild 17 d
*Data from pre-procedure transthoracic echocardiogram, unless indicated. yData from post-procedure transthoracic echocardiogram, unless indicated. zData from pre- or post-procedure transesophageal
echocardiogram. xThis patient was dismissed to palliative care 20 days after his valve-in-valve implantation. kThis patient suffered from hyperacute Melody valve failure due to valve thrombosis. He
underwent right-ventricular assist device placement 19 days after his valve-in-valve implantation and surgical tricuspid valve replacement 5 days later. For the purposes of calculating his functional status
after valve-in-valve implantation, surveillance was truncated at the time of his Melody valve failure.
NYHA ¼ New York Heart Association.
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Table 3. Procedure Characteristics
Mitral
Implantation Cases
Tricuspid
Implantation Cases
Procedure time, min 211  72 175  39
Fluoroscopy time, min 37.2  8.5 21 (15–33)
Contrast use, ml 92  79 40  42
Radiation dose, mGy 1,028  610 791 (298–1,566)
Radiation dose, Gy $ cm2 94  58 73 (31–157)
Values are mean  SD or median (interquartile range).
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603with previous early bioprosthetic failure experienced Melody
valve thrombosis 18 days after his procedure. He required
surgical tricuspid valve re-replacement with a homograft
valve. Pathological examination of the excised Melody valve
revealed an occlusive thrombus. Despite anticoagulation,
acute failure of the homograft tricuspid prosthesis occurred
within a few days of redo surgical tricuspid valve replace-
ment. Thrombophilia evaluation revealed heparin-induced
thrombocytopenia. The patient was listed for cardiac
transplantation and remains clinically stable despite bio-
prosthetic valve stenosis.
One mitral patient died of unknown causes 110 days after
his valve-in-valve procedure. At the time of this patient’s last
clinical contact with our institution, he had New York Heart
Association (NYHA) functional class III symptoms, only
a slight improvement from his pre-operative status. A
second mitral valve patient was dismissed to palliative care
due to persistent severe heart failure. He died the day after
hospital dismissal. A third mitral valve patient died of
unknown causes 19 days after her valve-in-valve procedure
and 12 days after hospital discharge. At the time of her last
contact with our institution, she reported NYHA functional
class II symptoms. Overall, NYHA functional class
improved in 8 of the 9 mitral valve patients and 9 of the
10 tricuspid valve patients (Fig. 3A) (p < 0.01).Figure 3. Change in NYHA Functional Class and Diastolic Inﬂow Gradient
(A) The change in New York Heart Association (NYHA) functional classiﬁcation for the
undergoing mitral (n ¼ 9) and tricuspid (n ¼ 10) valve-in-valve implantation.Discussion
The present study demonstrates the feasibility and clinical
efﬁcacy of percutaneous, transvenous valve-in-valve implan-
tation of the Melody valve for treatment of dysfunctional
bioprosthetic mitral and tricuspid valves. This series describes
a novel transvenous, transseptal technique utilizing an apical
rail to facilitate mitral valve-in-valve implantation. Percuta-
neous transvenous Melody valve implantation reduced inﬂow
obstruction and prosthetic valve regurgitation. In the
majority of patients, it improved clinical symptoms. The
procedure was safe and well tolerated, with no periprocedural
mortality. These ﬁndings support an emerging role for
percutaneous, transvenous implantation of the Melody valve
in patients with dysfunctional bioprosthetic mitral or
tricuspid valves in which repeat sternotomy and open cardiac
surgery carry substantial perioperative risk.
The Melody valve has an established role in the treatment
of right-sided compared with left-sided valvular disease
(18,27). Previous studies have suggested adequate perfor-
mance under systemic pressures or in the setting of
pulmonary hypertension (28). Our series adds to the
previous literature supporting the feasibility of Melody valve
implantation in higher pressure environments.
Other series of patients undergoing transcatheter valve-
in-valve implantation have used the Edwards Sapien valve
(Edwards Lifesciences, Irvine, California) (5,6,8). We chose
the Melody valve for several reasons. The Melody valve is
longer in length than the Edwards Sapien valve (29), facil-
itating coaxial alignment. The longer length of the Melody
valve also allows it to cover the entire dysfunctional bio-
prosthetic valve, so stenting the deployment site before
implantation is not necessary. At the time of our ﬁrst
procedures, the Melody valve was the only transcatheter
valve available for off-label use in the United States. Finally,
the Melody valve provided a favorable size proﬁle for our19 patients in this study. (B) Change in diastolic inﬂow gradient for the patients
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604patients. Although the reported internal diameter of the
dysfunctional bioprosthetic valves in our series was as high as
31 mm, the measured internal diameter ranged from 17 to
23 mm. This decrease in size reﬂects degeneration of the
dysfunctional prostheses. The Melody valve, by contrast,
expands up to 24.06 mm, with a small percentage of recoil
on the 22-mm Ensemble delivery system (30). Therefore,
the Melody valve provided an appropriate size proﬁle to ﬁt
the measured internal diameters of the dysfunctional bio-
prosthetic valves in our series.
The ﬁrst reported attempt at mitral valve-in-valve
implantation was unsuccessful due to an inability to align the
percutaneous valve in a coaxial position with the dysfunc-
tional bioprosthetic valve (4). Other series have overcome
this problem through implantation via a transapical
approach (5,6,8). Our approach uses a continuous rail from
the femoral vein, through the atrial septum, with exterior-
ization via the left ventricular apex. This facilitates coaxial
alignment of the percutaneous Melody valve with the
dysfunctional bioprosthetic valve, allows delivery from the
venous side, and minimizes the sheath size necessary to
access the left ventricle. In this series, our approach did not
result in any cases of valve embolization, poor valve align-
ment, or dysfunction of the Melody valves placed in the
mitral position.
Vascular complications occurred in 4 of 19 patients (21%)
in our series. All 4 vascular complications occurred on the
side of the venous sheath that we used for Melody valve
delivery. In 3 of the 4 cases, we also obtained arterial access
at the same site. It is likely that these vascular complications
were related to the large size of the venous sheath used for
Melody valve delivery, concurrent arterial access, and patient
comorbidities.
The left ventricular puncture carries established risks, with
complication rates documented as high as 30% to 40%
(22,31). In our series, 2 of 9 patients (22%) undergoing
mitral valve-in-valve implantation developed a left hemo-
thorax requiring chest tube drainage. No patients developed
pericardial tamponade, arrhythmias, or persistent pain
related to the left ventricular apical puncture. Therefore,
despite its risks, use of a left ventricular apical puncture as
part of the mitral valve-in-valve implantation procedure
seems an acceptable method to facilitate alignment of the
percutaneous valve.
Difﬁculty obtaining adequate coaxial alignment also
occurs during tricuspid valve-in-valve implantation. Some
authors have advocated an open transthoracic procedure to
facilitate alignment (4,32,33). However, our series demon-
strates that adequate alignment can occur through either
a transfemoral or transjugular approach and use of a rela-
tively ﬂexible support wire.
Our patients undergoing mitral valve-in-valve implanta-
tion were elderly and ill, with multiple comorbid conditions
and a mean STS mortality score of 13.3%. This is similar topatients in other valve-in-valve series (4–6,8). Despite their
high risk, patients tolerated the procedure well. Neverthe-
less, valve-in-valve therapy should be reserved for patients
whose surgical risk and comorbid medical conditions would
preclude surgical valve intervention.
Our group of 10 patients undergoing Melody valve
implantation in the tricuspid position included a hetero-
geneous range of pathology. The youngest 4 patients in
our group all had a history of congenital heart disease
requiring prior tricuspid valve replacement. The 6 older
patients underwent their initial tricuspid valve replacement
for tricuspid valve endocarditis in 1 case, carcinoid heart
disease in 1 case, rheumatic heart disease in 1 case, and
presumed functional tricuspid regurgitation in the other 3
cases. Previous reports describing tricuspid valve-in-valve
therapy have occurred in a similarly heterogeneous pop-
ulation, including children with congenital heart disease
(20,21,34), adults with congenital heart disease (21,35,36),
patients with prior infective endocarditis (21,37), and
patients with a history of rheumatic (21,33,38) or carci-
noid (32) heart disease. The success of the procedure in
our study group coupled with the positive outcomes from
prior reports suggest that tricuspid valve-in-valve therapy
has the potential to beneﬁt patients with a variety of
medical conditions leading to bioprosthetic tricuspid valve
failure.
All patients in our series had the beneﬁt of intraprocedural
imaging with TEE (n ¼ 12) or ICE (n ¼ 7). Imaging
support facilitated Melody valve sizing, Melody valve
alignment, and assessment of valve-in-valve function
immediately after implantation. We found 3-dimensional
echocardiography particularly useful for the assessment of
dysfunctional bioprosthetic valve morphology prior to valve-
in-valve implantation (Figs. 1A and 2A) and Melody valve
geometry after the procedure (Figs. 1E and 2F).
Study limitations. This is a single-institution, retrospective
review of patient records after percutaneous valve-in-valve
implantation of the Melody valve in the mitral or tricuspid
position. Patients were highly selected. Post-procedure care
may not have occurred at our institution, potentially limiting
our ability to capture all post-procedural events. Finally,
the immediate success of valve-in-valve implantation at
improving hemodynamics and patient symptoms may not
necessarily predict long-term outcomes. Study of larger
cohorts with prolonged surveillance will be necessary to
address this question. These will become possible as valve-
in-valve technology and implantation techniques mature.
Conclusions
We report a series of 19 patients undergoing percutaneous
transvenous Melody valve-in-valve implantation for treat-
ment of dysfunctional bioprosthetic mitral or tricuspid
valves. We also describe a novel technical approach utilizing
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 6 , 2 0 1 3 Cullen et al.
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605an apical rail to facilitate mitral valve-in-valve implantation.
Procedures were well tolerated and resulted in improved
valve function and heart failure symptoms. Longer surveil-
lance and larger cohorts are necessary to determine the
ultimate role of percutaneous valve-in-valve implantation in
degenerated bioprosthetic valves.
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